SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2148)3/1/2002 12:44:35 PM
From: 613  Respond to of 2515
 
Today is probably a lot of short covering due to yesterdays gains. We'll have to see what happens next week but I would expect a pullback to low 20's then it becomes a trading stock based on crazy evaluations - as it was before.
Will other competitors beat IMCL to market will be the next big question. It will be a close race. Even if they do get approval, the current price is probably a reasonable valuation. Other drugs in the pipeline are 1-2 years out.



To: Cacaito who wrote (2148)3/1/2002 3:11:12 PM
From: keokalani'nui  Read Replies (1) | Respond to of 2515
 
>>I would not expect the valuation to be the same as previous peak, unless extremely good data comes out of the German trial, and for what is available from the failed one not much should be expected.<<

I agree with your first claim. But you have HnN and the temporarily forgotten 1c11 coming on big at asco, with knowledge of those results in 60 days. No other cancer expresses egfr at a greater rate than HnN.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News